Specialty Overview

Best Hospitals for Lung Cancer Treatment in Delhi NCR, India

35 surgical oncology hospitals in our India network are listed in Delhi NCR, accredited by JCI, NABH, NABL, ISO, with 17,362 beds combined.

35
Hospitals Listed
1
City
4.5
Avg. Rating
4
Accreditation Types
The Short Answer

This page lists the surgical oncology hospitals in our directory offering Lung Cancer Treatment in Delhi NCR, India, including Apollo Hospitals, Medanta - The Medicity, Artemis Hospital, Fortis Memorial Research Institute and others. Each listing links through to the hospital's full profile page.

Ask us about lung cancer treatment in Delhi NCR, India

Share a few details and our care coordination team will get back to you with next steps.

Compare 35 accredited hospitals for Surgical Oncology in Delhi NCR, India

Starting from$1,000

🇮🇳 Apollo Hospitals

New Delhi, India 4.9 (1240 reviews) 1,000 beds
Why consider this hospital?
4.9/5 rating from 1240 reviewsAccredited by JCI, NABH1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by Apollo Hospitals's care team in New Delhi, India, from initial consultation through recovery. Apollo Hospitals, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.9/5
Rating
1983
Established
1,000
Beds
New Delhi, India
Location
Medanta - The Medicity
Starting from$1,000

🇮🇳 Medanta - The Medicity

Gurgaon, India 4.9 (2150 reviews) 1,600 beds
Why consider this hospital?
4.9/5 rating from 2150 reviewsAccredited by JCI, NABH1,600 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by Medanta - The Medicity's care team in Gurgaon, India, from initial consultation through recovery. Medanta - The Medicity, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.9/5
Rating
2009
Established
1,600
Beds
Gurgaon, India
Location
Artemis Hospital
Starting from$1,000

🇮🇳 Artemis Hospital

Gurgaon, India 4.9 (64 reviews) 750 beds
Why consider this hospital?
4.9/5 rating from 64 reviewsAccredited by JCI, NABH750 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgerySpine SurgeryBariatric Surgery
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by Artemis Hospital's care team in Gurgaon, India, from initial consultation through recovery. Artemis Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.9/5
Rating
2007
Established
750
Beds
Gurgaon, India
Location
Fortis Memorial Research Institute
Starting from$1,000

🇮🇳 Fortis Memorial Research Institute

Gurgaon, India 4.8 (1100 reviews) 1,000 beds
Why consider this hospital?
4.8/5 rating from 1100 reviewsAccredited by JCI, NABH1,000 beds
Specialties & Accreditation
Cardiac SurgeryCardiologyMedical OncologyBreast SurgeryBariatric SurgeryVascular Surgery
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by Fortis Memorial Research Institute's care team in Gurgaon, India, from initial consultation through recovery. Fortis Memorial Research Institute, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.8/5
Rating
1996
Established
1,000
Beds
Gurgaon, India
Location
Max Super Specialty Hospital
Starting from$1,000

🇮🇳 Max Super Specialty Hospital

New Delhi, India 4.8 (1300 reviews) 500 beds
Why consider this hospital?
4.8/5 rating from 1300 reviewsAccredited by JCI, NABH500 beds
Specialties & Accreditation
CardiacLiver Transplant
Accredited by JCI, NABH

Patients considering lung cancer treatment can be cared for by Max Super Specialty Hospital's care team in New Delhi, India, from initial consultation through recovery. Max Super Specialty Hospital, accredited by JCI, NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.8/5
Rating
2000
Established
500
Beds
New Delhi, India
Location
All India Institute of Medical Sciences (AIIMS)
Starting from$1,000

🇮🇳 All India Institute of Medical Sciences (AIIMS)

New Delhi, India 4.7 (3500 reviews) 2,400 beds
Why consider this hospital?
4.7/5 rating from 3500 reviewsAccredited by NABH2,400 beds
Specialties & Accreditation
Multi-specialtyResearch
Accredited by NABH

Patients considering lung cancer treatment can be cared for by All India Institute of Medical Sciences (AIIMS)'s care team in New Delhi, India, from initial consultation through recovery. All India Institute of Medical Sciences (AIIMS), accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.7/5
Rating
1956
Established
2,400
Beds
New Delhi, India
Location
CK Birla Hospital
Starting from$1,000

🇮🇳 CK Birla Hospital

Gurugram, Haryana, India 4.7 (162 reviews) 90 beds
Why consider this hospital?
4.7/5 rating from 162 reviewsAccredited by NABH90 beds
Specialties & Accreditation
Obstetrics & GynecologyOrthopedicsCardiac SciencesOncologyPediatrics
Accredited by NABH

Patients considering lung cancer treatment can be cared for by CK Birla Hospital's care team in Gurugram, Haryana, India, from initial consultation through recovery. CK Birla Hospital, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.7/5
Rating
2017
Established
90
Beds
Gurugram, Haryana, India
Location
Centre for Sight
Starting from$1,000

🇮🇳 Centre for Sight

Safdarjung Enclave, New Delhi, India 4.7 (181 reviews) 30 beds
Why consider this hospital?
4.7/5 rating from 181 reviewsAccredited by NABH30 beds
Specialties & Accreditation
LASIK SurgeryRetina SurgeryCataract SurgeryGlaucomaCornea Transplant
Accredited by NABH

Patients considering lung cancer treatment can be cared for by Centre for Sight's care team in Safdarjung Enclave, New Delhi, India, from initial consultation through recovery. Centre for Sight, accredited by NABH, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.7/5
Rating
1996
Established
30
Beds
Safdarjung Enclave, New Delhi, India
Location
Max Super Specialty Hospital, Gurgaon
Starting from$1,000

🇮🇳 Max Super Specialty Hospital, Gurgaon

Gurgaon, India 4.6 (95 reviews) 104 beds
Why consider this hospital?
4.6/5 rating from 95 reviewsAccredited by NABH, JCI104 beds
Specialties & Accreditation
Cardiac SciencesOncologyOrthopedicsNeurosciencesTransplant
Accredited by NABH, JCI

Patients considering lung cancer treatment can be cared for by Max Super Specialty Hospital, Gurgaon's care team in Gurgaon, India, from initial consultation through recovery. Max Super Specialty Hospital, Gurgaon, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.6/5
Rating
2007
Established
104
Beds
Gurgaon, India
Location
Max Super Speciality Hospital, Patparganj
Starting from$1,000

🇮🇳 Max Super Speciality Hospital, Patparganj

Patparganj, New Delhi, India 4.6 (97 reviews) 400 beds
Why consider this hospital?
4.6/5 rating from 97 reviewsAccredited by NABH, JCI400 beds
Specialties & Accreditation
Cardiac SciencesOncologyOrthopedicsNeurosciencesTransplant
Accredited by NABH, JCI

Patients considering lung cancer treatment can be cared for by Max Super Speciality Hospital, Patparganj's care team in Patparganj, New Delhi, India, from initial consultation through recovery. Max Super Speciality Hospital, Patparganj, accredited by NABH, JCI, follows recognised patient-safety and quality-of-care standards when performing lung cancer treatment.

4.6/5
Rating
2005
Established
400
Beds
Patparganj, New Delhi, India
Location
Our Methodology

How we selected these hospitals

A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.

What To Look For

How to Select the Best Hospital for Lung Cancer Treatment in Delhi NCR, India?

Choosing the right hospital for lung cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:

International Accreditation

Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.

Specialization

Check that the hospital's listed specialties actually include surgical oncology rather than only general care.

Capacity and Track Record

Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.

Transparent Costs

Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.

Clinical Overview

Understanding Lung Cancer Treatment

Lung cancer treatment encompasses a multidisciplinary spectrum of interventions — including anatomic resection, stereotactic body radiotherapy (SBRT), platinum-doublet chemotherapy, targeted molecular therapy (EGFR, ALK, ROS1 inhibitors), and immune checkpoint immunotherapy — tailored to histological subtype, stage, and genomic profile.

5–14 days (varies by modality: 5–7 days for VATS/robotic lobectomy; up to 14 days for open pneumonectomy or complex chemo-induction cases)
Hospital Stay
3–6 weeks (3 weeks post VATS/robotic resection or SBRT completion; 5–6 weeks post open thoracotomy or pneumonectomy; ongoing systemic therapy patients travel only after oncologist clearance and confirmed DVT prophylaxis plan)
Total Stay in Country (Fit-to-Fly)
70–90% 5-year survival (Stage I NSCLC with curative resection or SBRT); 40–65% objective response rate (Stage III–IV with targeted therapy or immunotherapy)
Success Rate

Clinical Overview

  • Lung cancer is a malignancy arising from the bronchial epithelium or alveolar parenchyma and is broadly classified into non-small cell lung cancer (NSCLC — comprising adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, accounting for ~85% of cases) and small cell lung cancer (SCLC, ~15% of cases).
  • NSCLC staging follows the TNM 9th Edition system (IASLC 2024), with Stage I–II disease amenable to curative-intent surgery or definitive radiotherapy, Stage III disease managed with concurrent chemoradiotherapy ± consolidation immunotherapy (e.g., durvalumab per the PACIFIC trial), and Stage IV disease approached with systemic therapy guided by comprehensive biomarker profiling.
  • SCLC is staged as limited-stage (LS-SCLC) or extensive-stage (ES-SCLC), with concurrent chemoradiation for LS-SCLC and platinum-etoposide plus atezolizumab or durvalumab for ES-SCLC.
Full details →

Who is a Candidate?

  • ELIGIBLE PATIENTS:
  • Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage seeking curative, consolidation, or palliative systemic/local therapy
  • Stage I–II NSCLC patients medically fit for anatomic pulmonary resection (lobectomy, segmentectomy) or SBRT — assessed by pulmonary function testing (FEV1 >40% predicted post-resection, DLCO >40%)
  • Stage III NSCLC patients eligible for concurrent chemoradiotherapy (PS ECOG 0–1, adequate cardiopulmonary reserve)
  • +25 more

Treatment Options & Approaches

  • SURGICAL APPROACHES:

Recovery

  • PHASE 1 — PRE-ARRIVAL PLANNING (2–4 Weeks Before Travel):

Risks to be aware of

  • Lung cancer treatment carries procedure- and modality-specific risks that patients must understand prior to consent.
  • For surgical resection (VATS/Robotic Lobectomy), risks include prolonged air leak (>5 days, occurring in 8–15% of cases), atrial fibrillation (15–20% post-lobectomy, most self-limiting), pneumonia (3–5%), bronchopleural fistula (<1% but potentially life-threatening), and in-hospital mortality of approximately 1–2% for lobectomy and 5–8% for pneumonectomy.
Full details →

Why GAF Healthcare

  • GAF Healthcare provides comprehensive end-to-end non-medical coordination that begins the moment a patient enquires and continues through post-departure remote follow-up.

Cost Range for Related Procedures

Cancer Surgery$4,000$15,000
Chemotherapy$1,000$4,000
Radiation Therapy$3,500$10,000
Get a personalised estimate with our cost calculator →

Common questions about Lung Cancer Treatment

What is the cost of lung cancer treatment in India compared to the UAE?
The cost of lung cancer treatment varies by modality and stage. In India, a VATS lobectomy (surgery alone, including hospital stay, anaesthesia, and standard medications) typically costs USD 6,000–12,000. A course of SBRT runs USD 4,000–8,000. A complete concurrent chemoradiotherapy programme (6–7 weeks) costs USD 8,000–18,000. First-line systemic therapy initiation (targeted agents or immunotherapy, per cycle) costs USD 1,500–5,000 per cycle depending on the drug. In the UAE (Dubai/Abu Dhabi), equivalent procedures cost approximately 60–100% more: VATS lobectomy USD 18,000–35,000; SBRT USD 15,000–28,000; concurrent CRT USD 22,000–55,000; and systemic therapy initiation USD 5,000–15,000 per cycle. Both destinations provide JCI-accredited hospitals, internationally trained thoracic oncologists, NGS-guided molecular profiling, and robotic surgical platforms. India offers the lowest cost globally for equivalent clinical quality, while the UAE offers premium private hospital environments and superior geographic convenience for patients from the GCC, East Africa, and the broader Arab world. GAF Healthcare provides a personalised itemised cost estimate within 48 hours of receiving your medical records, with no obligation to proceed.
How long do I need to stay in the country before I am fit to fly home after lung cancer treatment?
Fit-to-fly timelines are modality-specific and are determined by your thoracic surgeon or oncologist at the treating centre. After VATS or robotic-assisted lobectomy or segmentectomy, most patients are cleared for international flight at 3 weeks post-surgery, provided chest X-ray confirms no residual pneumothorax, pain is controlled on oral analgesia, and there are no signs of DVT on clinical assessment. Long-haul flights carry an elevated risk of deep vein thrombosis (DVT) and pulmonary embolism after thoracic surgery; all surgical patients receive a prescription for low molecular weight heparin (LMWH) and compression stockings for the return journey. After open thoracotomy or pneumonectomy, the fit-to-fly timeline is extended to 5–6 weeks, contingent on wound healing, stable spirometry, and cardiologist clearance. After SBRT, patients are typically cleared to fly 2–3 weeks after the final fraction once acute radiation reactions have settled. After the first cycle of chemotherapy, patients must wait until bone marrow nadir recovery — usually Day 14–21 — with white blood cell count above 3.0 × 10⁹/L and platelets above 100 × 10⁹/L before long-haul travel. Patients on oral targeted therapy (e.g., osimertinib, alectinib) may travel once tolerating the medication without significant side effects, typically 2–3 weeks after initiation. GAF Healthcare issues a formal fit-to-fly certificate from the treating physician, which is accepted by airlines for boarding with medical documentation.
What is the success rate of lung cancer treatment?
Success rates in lung cancer are stage- and modality-dependent and are best understood by specific disease scenario. For Stage I NSCLC treated with curative-intent VATS or robotic lobectomy, the 5-year overall survival rate is 70–90% (Stage IA3: 77–90%; Stage IB: 68–75% per IASLC data). SBRT for medically inoperable Stage I NSCLC achieves local control rates of 85–95% at 3 years, with 5-year overall survival of 40–60% (reflecting co-morbidities rather than oncological failure). For Stage II NSCLC with surgery ± adjuvant chemotherapy or osimertinib (ADAURA trial for EGFR-mutant disease, 88% DFS at 4 years), 5-year survival is 53–65%. For Stage III NSCLC managed with concurrent chemoradiotherapy plus durvalumab consolidation (PACIFIC regimen), median overall survival exceeds 47 months with a 5-year OS rate of approximately 42%. For Stage IV EGFR-mutant NSCLC treated with osimertinib, median progression-free survival is 18–25 months and median overall survival exceeds 38 months per the FLAURA data. For Stage IV ALK-rearranged NSCLC on alectinib, median PFS is 34 months. For high PD-L1 expressors (TPS ≥50%) on pembrolizumab monotherapy, 5-year OS rates of 31% have been reported in the KEYNOTE-024 trial — a remarkable benchmark for Stage IV disease. SCLC limited-stage achieves 5-year OS of 20–35% with concurrent chemoradiotherapy; extensive-stage SCLC median OS is 12–13 months with modern chemoimmunotherapy. GAF Healthcare's partner centres treat high volumes of thoracic oncology cases and submit outcomes data to international tumour registries, ensuring transparency and accountability.

How GAF Healthcare Assists in Choosing the Best Hospital for Lung Cancer Treatment in Delhi NCR, India

Discover the Top Hospitals for Lung Cancer Treatment in Delhi NCR, India

This page lists 35 accredited surgical oncology hospitals in Delhi NCR, India, so you can compare accreditation, specialties and bed capacity in one place.

Support When You Need It Most

Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.

Transparent, All-Inclusive Costs

We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.

Visa, Travel and Stay Coordination

Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.

Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.

Common Questions

Frequently asked questions about lung cancer treatment in Delhi NCR, India

How many surgical oncology hospitals are listed in Delhi NCR, India?
35 hospitals in our Delhi NCR, India directory are currently listed for surgical oncology including Lung Cancer Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Surgical Oncology is among its listed specialties and it is located in Delhi NCR, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in India?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Are there surgical oncology hospitals for this in other India cities?
See the "Hospitals in other cities" links on this page for the full India list.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including JCI, NABH, NABL, ISO — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for lung cancer treatment?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
🤔

Still have questions?

Our coordinators are here to answer your questions about lung cancer treatment in Delhi NCR, India.

Next Step

Share your medical reports with us and our team will recommend a hospital and treatment plan for lung cancer treatment in Delhi NCR, India.

Contact us to report an inaccuracy on this page.